The diagnostics company Gradientech today announces exclusive distribution agreements with the Triolab group for the commercialization of QuickMIC® in
"We are delighted to present Triolab as our distributor of our QuickMIC system for significant markets in
Gradientech already has an exclusive distribution agreement with Biomedica for the commercialization of QuickMIC® in
"By signing Triolab, being the leading distributor of the region in our market segment, we add another important piece in the foundation that will pivot us towards our goal of becoming the leading rapid AST solution", says
The QuickMIC system's ultra-rapid and precise results enable patients with sepsis to quickly receive specific personalized guidance of the right antibiotics in the right dose. The modular design makes it flexible and allows hospitals to start on a small scale and then scale up as needed.
"At Triolab group we want to secure that our customers have the possibility to use the most modern technology and give patients the best possible care. Sepsis is a life-threatening condition that develops as a reaction to infection and require emergency antibiotic therapy. As antibiotic resistance is a large and growing global threat and the current standard antibiotic susceptibility testing (AST) takes too long there is a need for faster diagnostics. We are therefore excited to start the collaboration with Gradientech to help hospitals provide rapid AST results in record-time, so that sepsis patients can receive proper targeted antibiotic treatment faster than ever before as well as fight antimicrobial resistance", says
For more information please contact:
Tel: + 46 763 29 08 14
peter.karlberg@gradientech.se
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance - one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala. Visit www.gradientech.se for more information.
About Triolab
https://news.cision.com/gradientech-ab/r/gradientech-signs-additional-distribution-agreement-for-europe,c3629416
https://mb.cision.com/Main/20108/3629416/1625647.pdf
https://news.cision.com/gradientech-ab/i/gradientech-lab,c3088343
(c) 2022 Cision. All rights reserved., source